Sharp, part of UDG Healthcare plc, a global leader in contract packaging and clinical supply services, has purchased new land as part of a $17 million investment into its Conshohocken, PA site.
The new 4-acre plot is directly adjacent to Sharp’s two existing commercial pharmaceutical packaging buildings, which collectively form the organization’s Blistering Centre of Excellence and is the latest addition to an ongoing capacity expansion project at the Conshohocken campus.
This land purchase will enable Sharp to add future capacity for cGMP packaging services and is part of a broader $43 million investment into its Pennsylvania operations which will increase the company’s blister packaging capacity by over 35% this year.
Mike DeAngelo, General Manager of Blistering and Bottling at Sharp said: “We make these capacity investments on behalf of our clients to ensure we have the capacity and capabilities to meet our commitment in providing world-class packaging services for them and their patients.
“This strategic land acquisition in Conshohocken and the broader investment at our site will allow us to plan for our future growth objectives while delivering against our commitments today.”
The Conshohocken investment to date includes the construction and fit out of six new primary GMP rooms as well as fit out for secondary packaging and installation of new blister lines.
The investment in Conshohocken is being made in addition to the recent announcement by Pennsylvania Governor Tom Wolf and his Action Team. The Governor confirmed support for Sharp’s plan to increase manufacturing capacity at its four-facility Allentown campus, through building improvements and new equipment and technology for its recently acquired 153,000 sq. ft. facility in Macungie. The company is slated to receive a $1.25 million state grant and a $140,000 grant to assist with worker training.
About Sharp
Sharp, part of UDG healthcare, is a global leader in advanced clinical supply chain services and contract pharmaceutical packaging. Offering solutions and support to pharma and biotech clients from phase I trials all the way through to commercialization and rapid launch. The organization has state-of-the-art facilities in the United States, United Kingdom, Belgium and the Netherlands and over 32 clinical depots globally, covering every region of the world.
Our full complement of integrated services includes analytical, formulation development, clinical manufacturing & packaging, clinical IRT, blister packaging, bottling, secondary assembly and labelling of injectable presentations, compliance packaging, as well as storage and distribution. Sharp also offers Qualified Person (QP) services for European distribution.
Through our partnership with Berkshire Sterile Manufacturing, we also offer specialist isolator-based filling of vials, syringes, cartridges and containers, as well as lyophilization and terminal sterilization.
